Lukasz Rzeczkowski

If you want to help create a future where: 1️⃣ people with rare diseases have faster diagnoses and better treatment options, and 2️⃣ innovators find a coordinated, sector-wide approach to get new tests and treatments to market, and help them stay there ➡️ read our latest report with Genetic Alliance UK: https://lnkd.in/e8iPr7Xi It recommends 10 actions that government, regulators, industry, academia, funders, clinicians, and patient groups can take to #ChangeTheRareFuture for those living with rare conditions.

119

A life science startup which graduated from a recent Accelerate@Babraham programme is fast-tracking progress towards clinical trials after landing a £3.5 million funding package from founding investor Delin Ventures and trumpeting its official launch. Based at Babraham Research Campus, Athernal Bio is developing new vaccines designed to lower the risk of cancer and certain age-related diseases. Its approach focuses on targeting early indicators of cancer with novel vaccine techniques to eliminate them, aiming to improve patient outcomes. Founded by Nirupa Desai and Ieuan Walker and incubated by Delin Ventures, Athernal Bio is developing what it describes as the first immunotherapies for high-risk clonal haematopoiesis (CH) — addressing blood cancer precursor condition with the aim of stopping cancer before it starts through early and proactive therapeutic intervention. CSO, Nirupa Desai, said: “CH is a well-recognised precursor to blood cancer, but no targeted treatment options currently exist. Patients can often live for years under the weight of knowing their condition could progress to AML, without any way to intervene. Our goal is to develop an immunotherapy that directly targets high-risk CH, with the aim of stopping cancer before it starts.” Athernal Bio CEO, Colin Freund added: “Athernal Bio is pioneering the treatment of high-risk clonal haematopoiesis with targeted immunotherapies. This represents a meaningful shift in oncology, moving away from reactive treatment to proactive prevention. The funding allows us to advance into in vivo validation and accelerate our path toward the clinic.” The investment by Delin Ventures will support in vivo proof-of-concept studies for CH treatment in preparation for an IND focused on this underserved patient group. Full article – https://lnkd.in/eecUnv5t

68

Nuclide Therapeutics, a British BioTech company and King's College London spin-out focused on developing targeted radiopharmaceuticals for therapy-resistant cancers, has raised €5.7 million in funding 🇬🇧🎗 The round saw participation from Marathon Beteiligungs AG, in what is reportedly the largest pre-money valuation of any King’s College London spin-out to date. Muhammet Tanc PhD, Co-founder, and CEO of Nuclide Therapeutics, commented: “The launch of Nuclide Therapeutics marks a bold step forward in our mission to give therapy-resistant cancer patients an effective treatment option.” https://lnkd.in/dnRnH6We

103

2 Comments

📢 Applications are now open for Accelerating FemTech: Evaluate, an Innovate UK Biomedical Catalyst Accelerator. This new 10-week programme offers tailored support to UK companies developing women’s health technologies at technology readiness level (TRL) 4+, with potential to address key challenges and conditions that affect women differently or disproportionally. Building on our work supporting early-stage innovations for women’s health, this hybrid programme is delivered with national partners to help companies grow, connect with the right people and plan testing of solutions in real-world healthcare settings, including cost-effectiveness. Participants will benefit from tailored business coaching, expert-led workshops, mentoring and targeted networking opportunities, as well as the ability to apply for a closed call funding opportunity from Innovate UK Biomedical Catalyst in Spring 2026. 👉 Applications for this Innovate UK Biomedical Catalyst funded accelerator are open until 11:59pm on 28 September: https://buff.ly/43dGmjV #BiomedicalCatalyst #FemTech #AcceleratingFemTechEvaluate

61

3 Comments

In a partnership between M42’s Danat Al Emarat and UK’s ProFaM, women can now extend their fertility or delay menopause using an innovative technique known as Ovarian Tissue Cryopreservation (OTC). This technology empowers women to take control of their reproductive health and reflects M42's commitment to shifting from traditional to reactive, proactive, and personalized healthcare. Learn more about this innovative technology through https://loom.ly/wL2mDI4 or https://loom.ly/faGD0qo. #M42 #CNN

47

2 Comments

At AMCE, innovation goes beyond technology - it’s about precision, people, and delivering an exceptional patient experience. In the latest feature by ARISE News, Dr. Boules Gabriel, MD, MBA, MRCP SCE, MSc Oncology, Clinical Director of Oncology, shares how AMCE is redefining cancer care in Africa by integrating state-of-the-art medical systems with world-class clinical expertise. He highlights AMCE’s investment in both advanced infrastructure and the skilled professionals who bring it to life - citing the radiotherapy department, where AI-powered linear accelerators with real-time imaging enable sub-millimetre tumor tracking, even as the patient breathes. This is not just about machines - it’s about building a sustainable, high-precision ecosystem of care. At AMCE, technology and talent converge to set a new benchmark for healthcare on the continent. #AMCE #HealthcareInnovation #MedicalExcellence #AfricaHealth #OncologyCare #HealthTech #FutureOfHealthcare #PatientCentredCare

116

3 Comments

Antimicrobial resistance (AMR) is one of the gravest public health threats confronting the world. AMR will cause 39 million deaths by 2050. This is a direct threat to the UK that demands urgent action, not short-sighted funding cuts. https://lnkd.in/e7e382wk

64

4 Comments